Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
So the question is: When is EndoRisk coming out?
Then call IR for clarification.
Clarinova stays with ELGL. Only US mining interests go to BRVO. Please go back and read the press release more carefully.
That will be true if their PRs have more meat to them rather the fluff in the previous ones this year. By fluff, I mean lack of any significant details like timing, distribution/sales usage, magnitude.
Hopefully this is the bottom with "tax selling" and we start the new year up.
Yea but what about KPAY? They’re gonna get the money. Lol.
Bird man likes to buy high and sell low. Just do the opposite and you'll make $$$$!
Of course he said that!
LOL. I’m hoping 2020!
Don't expect any PRED announcements until January. The market is in sleep mode with tax selling.
Thanks for passing that on, Stockboy.
This is good news about the US sales force. I assume that they are hiring the 8-10 sales people to address 80% of US market geographic areas.
Actually the BBs are pinching and energy is building for a bigger move. Stock is trading in very thin range right now.
Thing is they are not a reporting company
Agree - everyone is waiting for some concrete news from the company and not more fluff pieces that have no specifics.
23andMe might be working with another, superior, company instead. Just saying.
A great reason to never pay for this site
Like I said in previous post nothing new on call for people that know is going on. Thailand is a huge opportunity for the company. Buying only company that has all three licenses to grow distribution and retail cbd and all other products in Thailand!!! Big ride ahead for shareholders.
You didn't miss anything you probably don't already know
Agree both on the daily and 1 hour charts - both with positive divergences.
OpEx will be cut significantly to maintain operating margins for this quarter.
This RAFA call will be sell the news. Typical action for an OTC stock.
What's the call in info and is it 4:30PM EST?
People get bored and/or impatient and decide to move on. Timeline unknown but this will go higher over time.
In the annual report as of Jan 31, 2019, the company only had 83,866,999 shares outstanding. Now, as of 11/5/2019, they have 93,166,999; almost 10M more shares outstanding. So much for no dilution!
I kind of doubt that will happen. US, like Canada, has more pot than we can handle now.
Birdman has experience losing money. Always do the opposite and you will win. He trades momentum with translates to buy high and sell low.
This isn't a US operation. Why would the US law change matter?
Silverbugz why do you say that? Nothing has happened here for a while.
Heard the same thing. Company does not want to get those aholes the satisfaction that they caused issues. So it will not be disclosed.
The continuing large bid blocks are indicators that funds are continuing to buy. Even though this is painful right now, we will be rewarded for our patience.
Couldn't agree with you more. You are spot on and I hope the buyers are long term holders that people think they are.
Both announcements were very short on specifics. How much will they sell for and how will they be sold? When will sales start? How can you announce a product is available and not be ready for it. They are short on execution.
Long but tired.
Okay so EXAS sells Cologuard for around $480 per test. TTM revenue is $724M. Their stock price is 16 times sales and they are losing money.
So if PRED can make $500M in revenue with strong margins and its market cap was 16 times sales or $8B that would make it's stock price around $24/share. Just something to think about while we are arguing about billions in revenue in the next 2-3 years on 3 products.
This is why I am here. It's not for the stem cells.
No that's Fertility DX
That said I am confused by some of the math he uses.
Good math but it's $3,300 per test; not $500.
As far as I am concerned, they decided to throw out all the bad and trash in this past quarter. That's what large cap companies do as well. Clear the decks and get ready for the upswing!
I agree - at some point they will.
Good article. 351 is obviously a superior pathway for future product protection from competitors. Hopefully PRED has a big jumpstart.